Trevi Therapeutics(US:TRVI)2025-05-08 20:12Financial Performance - Trevi Therapeutics reported a net loss of $10.3 million for Q1 2025, compared to a net loss of $10.9 million in Q1 2024, reflecting a decrease of approximately 5.5%[6] - The company reported total operating expenses of $11.5 million for Q1 2025, a slight decrease from $11.9 million in Q1 2024[17] - The weighted average common shares used in net loss per share increased to 117,610,750 in Q1 2025 from 99,517,212 in Q1 2024[17] Research and Development - Research and development expenses decreased to $7.8 million in Q1 2025 from $8.8 million in the same period in 2024, primarily due to reduced clinical development expenses[4][5] - The Phase 2a RIVER trial showed a statistically significant reduction in 24-hour cough frequency of 67% from baseline and 57% on a placebo-adjusted basis in patients with refractory chronic cough[4] - Enrollment in the Phase 2b CORAL trial for chronic cough in IPF patients was completed in February 2025, with topline results expected in Q2 2025[4][2] - Trevi Therapeutics is reviewing the full data set from the RIVER trial and designing the next planned trial for Haduvio in patients with refractory chronic cough[4] Cash Position - The company ended Q1 2025 with $103.3 million in cash, cash equivalents, and marketable securities, providing a cash runway into Q4 2026[4] General and Administrative Expenses - General and administrative expenses increased to $3.7 million in Q1 2025 from $3.1 million in Q1 2024, mainly due to higher personnel-related expenses[6] Company Outlook - Trevi Therapeutics is positioned at a pivotal moment with promising data and a strong balance sheet to support the continued development of Haduvio[2]